Related Experiment Video

Updated: Jan 2, 2026

Utilizing Percutaneous Ventricular Assist Devices in Acute Myocardial Infarction Complicated by Cardiogenic Shock
06:10

Utilizing Percutaneous Ventricular Assist Devices in Acute Myocardial Infarction Complicated by Cardiogenic Shock

Published on: June 12, 2021

3.6K

Clinical predictors of pocket hematoma after cardiac device implantation and replacement

Sonia Ferretto1,2, Giulia Mattesi1, Federico Migliore1

  • 1Department of Cardiac, Thoracic and Vascular Sciences, University of Padua.

Journal of Cardiovascular Medicine (Hagerstown, Md.)
|December 3, 2019
PubMed

Insights

Low ejection fraction and certain antithrombotic therapies increase pocket hematoma risk after cardiac device procedures. Avoid low-molecular-weight heparin (LMWH) and dual antiplatelet therapy in these patients.

Area of Science:

  • Cardiology
  • Medical Device Technology
  • Pharmacology

Background:

  • Pocket hematoma is a frequent complication following cardiac implantable electronic device (CIED) procedures.
  • Optimizing perioperative antithrombotic management is crucial for patient safety.

Purpose of the Study:

  • To identify clinical factors associated with pocket hematoma formation after CIED implantation or replacement.
  • To determine the optimal perioperative antithrombotic strategy to minimize hematoma risk.

Main Methods:

  • Retrospective analysis of 500 consecutive patients undergoing CIED implantation or replacement.
  • Evaluation of patient data including antithrombotic therapy, left ventricular ejection fraction (LVEF), and procedure type.
  • Multivariate analysis to identify predictors of pocket hematoma.

Main Results:

  • The overall incidence of pocket hematoma was 4.6% after implantation and 4.4% after replacement.
  • Low-molecular-weight heparin (LMWH) use was associated with a significantly higher hematoma rate (11.0%).
  • Predictors of pocket hematoma included dual antiplatelet therapy (OR 6.3), LVEF < 30% (OR 7.4), and LMWH use (OR 3.8).

Conclusions:

  • Low LVEF and the use of LMWH are significant risk factors for pocket hematoma post-CIED procedures.
  • Combination therapy of anticoagulants with dual antiplatelet agents and LMWH should be avoided to reduce hematoma incidence.
Abstract

More Related Videos

Implantation of the Syncardia Total Artificial Heart16:11

Implantation of the Syncardia Total Artificial Heart

Published on: July 18, 2014

35.9K
Echocardiographic Evaluation of Atrial Communications before Transcatheter Closure07:41

Echocardiographic Evaluation of Atrial Communications before Transcatheter Closure

Published on: February 8, 2022

4.2K

Related Concept Videos

Cardiomyopathy VII: Pre and Post Operative Nursing Management01:28

Cardiomyopathy VII: Pre and Post Operative Nursing Management

Patients with hypertrophic cardiomyopathy (HCM) and left ventricular outflow tract (LVOT) obstruction who remain symptomatic despite optimal medical therapy may undergo a septal myectomy (Morrow procedure). This procedure involves excising a portion of the hypertrophied septum below the aortic valve using a heart-lung machine to improve blood flow through the LVOT. Effective preoperative and postoperative nursing management ensures successful patient outcomes, minimizes complications, and...
235
Cardiac Catheterization II: Right Heart Catheterization01:21

Cardiac Catheterization II: Right Heart Catheterization

Right Heart Catheterization: An OverviewRight heart catheterization is an invasive diagnostic procedure that measures right-sided cardiac and pulmonary artery pressures, calculates cardiac output, and identifies intracardiac shunts. It provides detailed hemodynamic data essential for diagnosing and managing various cardiovascular conditions, such as pulmonary hypertension.Access SitesCommon access sites for right heart catheterization include the internal jugular vein in the neck region, the...
665
Blood Studies for Cardiovascular System I: Cardiac Biomarkers01:20

Blood Studies for Cardiovascular System I: Cardiac Biomarkers

Cardiac biomarkers are enzymes, proteins, and hormones released into the blood when cardiac cells are injured. They are powerful tools for triaging.
The essential diagnostic tools for detecting myocardial necrosis and monitoring individuals suspected of having acute coronary syndrome (ACS) include:
Troponins
Troponins, particularly cardiac troponins I and T, are the most precise and sensitive markers of myocardial injury. They are detectable within 4-6 hours of myocardial injury and remain...
731
Cardiomyopathy II: Dilated Cardiomyopathy01:30

Cardiomyopathy II: Dilated Cardiomyopathy

Dilated cardiomyopathy, or DCM, is a progressive myocardial disorder characterized by ventricular chamber dilation and contractile dysfunction.EtiologyVarious factors can cause DCM, including hypertension and heavy alcohol intake, which contribute to the weakening and enlargement of the heart muscle. Viral infections, such as Coxsackievirus B, adenoviruses, and influenza, can lead to DCM by causing inflammation and damage to heart tissue. Certain chemotherapeutic agents, including daunorubicin,...
405
Cardiomyopathy III: Hypertrophic Cardiomyopathy01:29

Cardiomyopathy III: Hypertrophic Cardiomyopathy

Hypertrophic cardiomyopathy, or HCM, is an autosomal dominant genetic disorder characterized by asymmetric left ventricular hypertrophy without ventricular dilation. It is more common in men and is typically diagnosed in young, athletic adults.EtiologyHCM is primarily genetic and is caused by mutations in genes encoding sarcomeric proteins. Researchers have identified over 1400 mutations across at least 11 different genes. Among these, the most frequently occurring mutations are found in the...
325